Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been given a consensus rating of “Buy” by the eight analysts that are presently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $11.58.
A number of analysts recently issued reports on the company. Oppenheimer set a $13.00 price objective on ADMA Biologics and gave the stock a “buy” rating in a research report on Wednesday, September 5th. Maxim Group reissued a “buy” rating and set a $12.00 price objective on shares of ADMA Biologics in a research report on Wednesday, September 5th. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Chardan Capital assumed coverage on ADMA Biologics in a research report on Monday, July 30th. They set a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine raised ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, July 26th.
Shares of NASDAQ:ADMA opened at $5.49 on Wednesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 10.65 and a quick ratio of 8.88. The stock has a market cap of $260.48 million, a P/E ratio of -2.87 and a beta of 2.28. ADMA Biologics has a 12-month low of $2.03 and a 12-month high of $6.96.
ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $4.66 million for the quarter, compared to analyst estimates of $5.35 million. ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. On average, sell-side analysts forecast that ADMA Biologics will post -1.36 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AMP Capital Investors Ltd acquired a new position in ADMA Biologics in the 2nd quarter valued at about $109,000. Renaissance Technologies LLC acquired a new position in ADMA Biologics in the 2nd quarter valued at about $132,000. Schwab Charles Investment Management Inc. acquired a new position in ADMA Biologics in the 2nd quarter valued at about $160,000. Spark Investment Management LLC grew its position in ADMA Biologics by 68.7% in the 2nd quarter. Spark Investment Management LLC now owns 37,460 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 15,260 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in ADMA Biologics in the 1st quarter valued at about $182,000. 55.07% of the stock is owned by institutional investors.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Recommended Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.